A. DeMichele

1.6k total citations
39 papers, 193 citations indexed

About

A. DeMichele is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. DeMichele has authored 39 papers receiving a total of 193 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in A. DeMichele's work include Advanced Breast Cancer Therapies (14 papers), Cancer Treatment and Pharmacology (9 papers) and Breast Cancer Treatment Studies (8 papers). A. DeMichele is often cited by papers focused on Advanced Breast Cancer Therapies (14 papers), Cancer Treatment and Pharmacology (9 papers) and Breast Cancer Treatment Studies (8 papers). A. DeMichele collaborates with scholars based in United States, Italy and Australia. A. DeMichele's co-authors include Charles H. Graham, Laura van ‘t Veer, DB Cines, Philip Samuels, Maggie C.U. Cheang, Kathleen Conway, LA Carey, D. A. Berry, J. Gray and Laura J. Esserman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

A. DeMichele

36 papers receiving 182 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. DeMichele United States	8	109	83	40	31	30	39	193
Ekaterina A. Alekseeva Russia	8	64 0.6×	56 0.7×	30 0.8×	108 3.5×	97 3.2×	21	287
Ahmed Kamel Egypt	5	111 1.0×	40 0.5×	51 1.3×	90 2.9×	10 0.3×	15	287
Nicole E. James United States	12	91 0.8×	81 1.0×	53 1.3×	75 2.4×	5 0.2×	32	298
Tatjana Božanović Serbia	9	63 0.6×	39 0.5×	14 0.3×	70 2.3×	11 0.4×	19	182
Teresa Staiano Italy	11	118 1.1×	66 0.8×	72 1.8×	77 2.5×	20 0.7×	19	289
Eleonora Zanetti Italy	10	80 0.7×	31 0.4×	31 0.8×	77 2.5×	7 0.2×	29	253
Stephen Chanock United States	8	76 0.7×	58 0.7×	53 1.3×	135 4.4×	47 1.6×	10	266
In-Pyo Baek South Korea	7	141 1.3×	176 2.1×	68 1.7×	116 3.7×	10 0.3×	10	329
Davide Mari Italy	7	115 1.1×	40 0.5×	83 2.1×	210 6.8×	65 2.2×	8	358
Liudmila Velikokhatnaya United States	6	95 0.9×	76 0.9×	40 1.0×	113 3.6×	6 0.2×	7	359

Countries citing papers authored by A. DeMichele

Since Specialization

Citations

This map shows the geographic impact of A. DeMichele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. DeMichele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. DeMichele more than expected).

Fields of papers citing papers by A. DeMichele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. DeMichele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. DeMichele. The network helps show where A. DeMichele may publish in the future.

Co-authorship network of co-authors of A. DeMichele

This figure shows the co-authorship network connecting the top 25 collaborators of A. DeMichele. A scholar is included among the top collaborators of A. DeMichele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. DeMichele. A. DeMichele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Tolaney, Sara M., Nadine Tung, Antonio C. Wolff, et al.. (2024). HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open. 9(12). 103987–103987. 8 indexed citations

2.

Waks, Adrienne G., Guillermo Villacampa, Nadine Tung, et al.. (2023). 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies. ESMO Open. 8(1). 101465–101465. 1 indexed citations

3.

Gottipati, Srikanth, Helena Earl, Christina Yau, et al.. (2023). 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study. Annals of Oncology. 34. S325–S326. 1 indexed citations

4.

Rugo, H. S., Adam Brufsky, Lynn McRoy, et al.. (2022). 169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis. Annals of Oncology. 33. S202–S202. 2 indexed citations

5.

Lu, Jianqin, G. T. Budd, Sophia Frentzas, et al.. (2022). 250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation. Annals of Oncology. 33. S223–S223. 1 indexed citations

6.

O’Shaughnessy, Joyce, A. DeMichele, X. Cynthia, et al.. (2017). Abstract P4-22-04: A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation. Cancer Research. 77(4_Supplement). P4–22. 1 indexed citations

7.

DeMichele, A., P.N. Munster, Othon Iliopoulos, et al.. (2017). Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC). Cancer Research. 77(4_Supplement). P6–11. 1 indexed citations

8.

Hurvitz, SA, DA Yardley, Amelia Zelnak, et al.. (2017). Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cancer Research. 77(4_Supplement). OT2–1. 2 indexed citations

9.

Meric‐Bernstam, Funda, Nizar M. Tannir, James J. Harding, et al.. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). European Journal of Cancer. 69. S12–S13. 9 indexed citations

10.

Stricker, Carrie Tompkins, Linda A. Jacobs, A. DeMichele, et al.. (2011). Survivorship care plan assessment checklist (SCPAC): A tool to evaluate breast cancer survivorship care plans.. Journal of Clinical Oncology. 29(15_suppl). 6117–6117. 2 indexed citations

11.

Perini, Rodolfo F., A. DeMichele, David J. Vaughn, et al.. (2011). Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1.. Journal of Clinical Oncology. 29(15_suppl). 3088–3088. 2 indexed citations

12.

Feng, Rennan, et al.. (2010). Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors.. Journal of Clinical Oncology. 28(15_suppl). 526–526. 1 indexed citations

13.

DeMichele, A., Marc E. Lenburg, Joe W. Gray, et al.. (2009). Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657).. Cancer Research. 69(24_Supplement). 2003–2003. 1 indexed citations

14.

Freeman, Ellen W., et al.. (2009). Ovarian aging after chemotherapy: a game of chutes and ladders. Fertility and Sterility. 92(3). S1–S1. 1 indexed citations

15.

DeMichele, A., Lara Dunn, Phyllis A. Gimotty, et al.. (2009). Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657). Journal of Clinical Oncology. 27(15_suppl). 11091–11091. 1 indexed citations

16.

Esserman, Laura J., Maggie C.U. Cheang, A. DeMichele, et al.. (2009). Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). Journal of Clinical Oncology. 27(18S). LBA515–LBA515. 2 indexed citations

17.

Esserman, Laura J., Maggie C.U. Cheang, A. DeMichele, et al.. (2009). Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). Journal of Clinical Oncology. 27(15_suppl). LBA515–LBA515. 29 indexed citations

18.

Matro, Jennifer M., et al.. (2008). Clinical and genetic risk factors for bone loss in breast cancer survivors after adjuvant chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 578–578. 1 indexed citations

19.

Alton, John, et al.. (2007). Relationships between clinical and biochemical predictors of chemotherapy-related amenorrhea in premenopausal adjuvant breast cancer patients. Journal of Clinical Oncology. 25(18_suppl). 11011–11011. 4 indexed citations

20.

O’Dwyer, Peter J., Patricia LoRusso, A. DeMichele, et al.. (2007). A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991. Journal of Clinical Oncology. 25(18_suppl). 3550–3550. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact